We at Glenmark relentlessly strive to make the lives of patients better globally.

With offices in over 40 countries, 17 manufacturing facilities across 5 countries and 5 R&D centers around the world, our dedication to enriching lives worldwide knows no bounds.

Our vision has led us to discover new molecules that can make a difference to patients globally. As we look to the future, we are focused on developing high-quality generics and specialty products for markets across the globe.

One of the real factors behind our success is our team of more than 12,000 employees from over 60 nationalities, who come together to make a new way for a new world.

Type
Public
HQ
Mumbai, IN
Founded
1977
Size (employees)
7,000 (est)
Glenmark Pharmaceuticals was founded in 1977 and is headquartered in Mumbai, IN
Report incorrect company information

Glenmark Pharmaceuticals Office Locations

Glenmark Pharmaceuticals has an office in Mumbai
Mumbai, IN (HQ)
Western Express Hwy
Show all (1)
Report incorrect company information

Glenmark Pharmaceuticals News and Updates

Glenmark Pharmaceuticals Announces FDA Acceptance of the Company's First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis

MAHWAH, N.J., Aug. 7, 2018 /PRNewswire/ -- Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the company's New Drug Application for its leading respiratory pipeline candidate Ryaltris™ (rye -...

Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

MUMBAI, India and LA CHAUX DE FONDS, Switzerland and BOSTON and SHANGHAI, Aug. 6, 2018 /PRNewswire/ -- Glenmark Pharmaceuticals S.A. and Harbour BioMed announced today that they have entered into an exclusive license agreement for the Greater China territory to develop, manufacture and...

Glenmark Pharmaceuticals and Harbour BioMed enter into strategic license agreement

For development and commercialization of Glenmark's bispecific antibody - GBR 1302

Glenmark Pharmaceuticals Ltd up for fifth session

The stock is quoting at Rs 582.5, up 0.5% on the day as on 12:44 IST on the NSE. Glenmark Pharmaceuticals Ltd is down 16.77% in last one year as compared to a 11.67% spurt in NIFTY and a 3.56% spurt in the Nifty Pharma.

Glenmark Pharmaceuticals update on phase 1 study for GBR 310

A proposed biosimilar and reference product omalizumab

The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals' Manufacturing Facility in Monroe, North Carolina

PARAMUS, N.J., June 18, 2018 /PRNewswire/ -- Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the U.S. Food & Drug Administration provided its first supplemental Abbreviated New Drug Application (sANDA) approval for the company's manufacturing facility...
Report incorrect company information

Glenmark Pharmaceuticals Company Life and Culture

Report incorrect company information